NewsBenzingaアクラリスの抗TSLP抗体ボサキツグを用いたアトピー性皮膚炎に対する第2相ADMIRATION試験、24週時のEASI変化率という主要評価項目を達成できず、副次評価項目も未達成 アクラリスの抗TSLP抗体ボサキツグを用いたアトピー性皮膚炎に対する第2相ADMIRATION試験、24週時のEASI変化率という主要評価項目を達成できず、副次評価項目も未達成 Benzinga 2026.11.16 08:34 (GMT+0) Open on Benzinga Other news A whale accumulates 238,400 LINK from Binance in two days, worth about $2.2 million Huobi HTX to Open Spot Trading for SOXS, KORU and SNXX on November 17 Duan Yongping Trims Nvidia and Apple in Q3, Exits Alibaba and CRCL, Opens New SpaceX Stake Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds US Says Justice Leads Megaspeed AI-Chip Investigation Soluna Holdings, Inc. (SLNH) Q3 2026 Earnings Call Transcript
Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds